Reimbursement Review Reports


( Last Updated : November 26, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Atectura Breezhaler indacaterol /mometasone furoate Asthma maintenance (adults, children 12 or older) Reimburse with clinical criteria and/or conditions Complete
Atriance Nelarabine Cancelled
Atripla Efavirenz, emtricitabine, tenofovir disoproxil fumarate HIV List with clinical criteria and/or conditions Complete
Aubagio Teriflunomide Multiple sclerosis, relapsing-remitting Do not list at the submitted price Complete
Avastin Bevacizumab Cervical Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Platinum Resistant Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Avastin Bevacizumab Withdrawn
Avastin (with capecitabine) Bevacizumab Metastatic Colorectal Cancer Reimburse with clinical criteria and/or conditions Complete
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete